23andMe Holding Co - Multiplikator nilai perusahaan marang pendapatan ME

Is it worth investing in 23andMe Holding Co. (ME), a pioneer of personalized genetics that has built a massive DNA archive for drug development? The shift in EV/Sales valuation provides the answer, with indicating the current level. The business relies on valuable biodata for pharma behemoths, despite elastic demand in the retail sector. However, a profound crisis of trust and declining interest in DNA testing threaten the company's survival.
ME (23andMe Inc.): rincian analitis lan laporan miturut indikator

For a fundamental valuation of 23andMe Holding Co. (ME), it is critical to understand the ratio of enterprise value to annual sales on an unlevered basis. By analyzing the EV/Revenue trend, an investor determines the market revaluation of assets, where the stability of this metric confirms the effectiveness of diversification between B2C tests and B2B partnerships with pharma behemoths, minimizing data commercialization risks.